Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials.
BACKGROUND
There is growing concern about the ability of clinical trials to reliably detect differences between active drugs and placebo. To date, little attention has focused on how interactions between clinical trial investigators and patients may influence study outcomes. We sought to explore what types of interactions with patients investigators considered to be appropriate during placebo-controlled pharmacotherapy studies of major depressive disorder.


METHODS
Questionnaires describing 26 specific types of clinician-patient interactions were administered to principal investigators (PIs) attending an investigators meeting for a phase 3 clinical trial of an antidepressant medication. Principal investigators were asked to rate the acceptability of each intervention. They were also asked to report the mean time they spent with patients at a midstudy visit. Principal investigators were grouped according to previous trial experiences (participation in <20 or > or =20 prior trials).


RESULTS
Principal investigators generally agreed that physical health recommendations and nonspecific interactions with study patients were acceptable. Relating the investigator's personal experiences and siding with the patient on interpersonal conflicts were consistently rated as unacceptable. Less-experienced PIs were significantly more likely to view as acceptable cognitive, behavioral, and emotionally supportive interventions compared with more-experienced PIs. Forty-two percent of PIs reported spending at least 20 minutes with patients at midstudy visits.


CONCLUSIONS
There is significant variability between PIs in what are considered to be appropriate interactions with patients participating in clinical trials. Greater standardization of these interactions is required to reduce placebo response rates and to strengthen the ethical conduct of clinical trials.
Dunlop
Boadie W
BW
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA. bdunlop@emory.edu
Vaughan
Christopher L
CL
D017326:Clinical Trials, Phase III as Topic / Q000941:ethics* / Q000592:standards; D003625:Data Collection; D003865:Major Depressive Disorder / Q000628:therapy; D006801:Humans; D015337:Multicenter Studies as Topic / Q000941:ethics* / Q000592:standards; D010817:Physician-Patient Relations / Q000941:ethics*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics* / Q000592:standards; D012108:Research Personnel / Q000941:ethics* / Q000592:standards; D013997:Time Factors
J Clin Psychopharmacol. 2001 Apr;21(2):251-2
11270933
N Engl J Med. 2008 Jan 17;358(3):252-60
18199864
Clin Psychol Rev. 2005 Jun;25(4):459-86
15893862
J Clin Psychiatry. 2007 Aug;68(8):1213-7
17854245
JAMA. 2002 Apr 10;287(14):1840-7
11939870
Psychopharmacologia. 1966;9(5):392-418
4872909
J Affect Disord. 2006 Jun;92(2-3):287-90
16503356
Am J Psychiatry. 2005 Mar;162(3):628
15741493
J Med Ethics. 2009 Jun;35(6):384-9
19482985
Eur Psychiatry. 2007 Oct;22(7):419-26
17482798
Psychopharmacol Bull. 1987;23(2):309-24
3303100
J Consult Clin Psychol. 1996 Jun;64(3):532-9
8698947
Clin Psychol Rev. 2006 Jan;26(1):17-31
16199119
Psychopharmacol Bull. 2008;41(4):65-75
19015630
J Clin Psychopharmacol. 2007 Feb;27(1):1-5
17224705
J Clin Psychiatry. 1997;58 Suppl 11:30-8
9363046
PLoS Med. 2008 Feb;5(2):e45
18303940